Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Iscucin Populi is an anthroposophic mistletoe (*Viscum album*) preparation produced by harvesting mistletoe from poplar trees (*Populus*). Developed and manufactured by WALA Heilmittel, it is part of a range of mistletoe extracts used primarily in integrative oncology and supportive cancer care. The preparation contains various biologically active components, most notably mistletoe lectins (ML I, II, and III) and viscotoxins. Iscucin Populi is designed to stimulate the immune system, specifically increasing the activity of natural killer (NK) cells and T-lymphocytes, while also exerting pro-apoptotic and cytotoxic effects on tumor cells. It is typically administered via subcutaneous injection and is used to improve the quality of life and immune function in patients undergoing cancer treatment.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Iscucin Populi.